No Picture
News

Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active h… […]

No Picture
News

Atreca Announces Strategic Research Collaboration with Merck to Identify Novel Antibody Targets in Oncology

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation … […]

No Picture
News

Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial resul… […]

No Picture
News

Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., Aug. 13, 2019 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial resul… […]

No Picture
News

Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel

REDWOOD CITY, Calif., July 11, 2019 (GLOBE NEWSWIRE) — Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa … […]